DiaMedica Therapeutics Inc
NASDAQ:DMAC
DiaMedica Therapeutics Inc
Cash from Financing Activities
DiaMedica Therapeutics Inc
Cash from Financing Activities Peer Comparison
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
DiaMedica Therapeutics Inc
NASDAQ:DMAC
|
Cash from Financing Activities
$36.8m
|
CAGR 3-Years
8%
|
CAGR 5-Years
12%
|
CAGR 10-Years
20%
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
16%
|
CAGR 10-Years
-7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is DiaMedica Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
36.8m
USD
Based on the financial report for Dec 31, 2023, DiaMedica Therapeutics Inc's Cash from Financing Activities amounts to 36.8m USD.
What is DiaMedica Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
20%
The average annual Cash from Financing Activities growth rates for DiaMedica Therapeutics Inc have been 8% over the past three years , 12% over the past five years , and 20% over the past ten years .